NVS and NVO: Which Has Higher Upside Potential?



Valuation comparison

Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1. The stock is trading at a forward PE (price-to-earnings) ratio of 13.3, and its PEG (price-to-earnings-to-growth) ratio is 2.2. At present, Novartis’ price-to-sales ratio is 3.6, and its price-to-book ratio is 2.4.

The company’s operating margin is 18.5%. Novartis has generated an ROA (return on assets) of 4.4% and an ROE (return on equity) of 10.3%. The company has a payout ratio of ~87%, meaning it distributes ~87% of its earnings as dividends to shareholders.

In comparison, Novo Nordisk’s (NVO) EV is $117.3 billion, and its EV-to-revenue ratio is 6.4. The stock trades at a forward PE ratio of 16.8, and its PEG ratio is 2.5. Novo Nordisk’s price-to-sales ratio is 6.2, and its price-to-book ratio is 14.0.

Novo Nordisk far outscores Novartis based on operating margins, ROA, and ROE. Novo Nordisk’s operating margin is at a healthy 44%. Its ROA is 30.7%, and its ROE is 80.2%, suggesting Novo Nordisk is making better use of shareholders’ capital to generate returns.

Article continues below advertisement

Analysts’ recommendations

Of the four analysts covering Novartis in April, two recommended “buy” or a higher rating, one recommended “hold,” and one recommended “sell.” The stock’s mean rating is 2.5, and its target price is $92.67, implying an upside potential of 21.3%.

In comparison, the one analyst covering Novo Nordisk recommended “strong buy.” The stock’s target price of $60.40 implies an upside potential of 28.8% based on its current price of $46. In the next part of this series, we’ll compare Sanofi and GlaxoSmithKline.


More From Market Realist